Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionIntegrated Wealth Concepts LLC
Latest Disclosed Ownership5,374 shares
Latest Disclosed Value $ 1,778,185
Integrated Wealth Concepts LLC reports 26.75% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Integrated Wealth Concepts LLC filed a 13F-HR form disclosing ownership of 5,374 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $1,535,352 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 4,240 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 26.75% during the quarter. The current value of the position is $1,353,173 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 5,374 1,134 26.75 1,778 5.46 0.0142
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 4,240 -396 -8.54 1,686 -20.25 0.0200
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 4,636 1,191 34.57 2,114 88.25 0.0189
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 3,445 706 25.78 1,123 51.96 0.0113
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,739 227 9.04 740 25.04 0.0086
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,512 176 7.53 591 -7.94 0.0069
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,336 22 0.95 642 14.23 0.0078
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,314 -6 -0.26 562 62.43 0.0077
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,320 31 1.35 347 -21.00 0.0050
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,289 15 0.66 438 8.96 0.0072
2023-11-15 2023-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,274 3 0.13 403 -6.73 0.0071
2023-08-15 2023-06-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,271 -135 -5.61 431 0.0074
2023-05-03 2023-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,406 2,406 0 0.0099
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.